Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA dynamics during Encorafenib + Binimetinib induction and subsequent immunotherapy in metastatic melanoma
NL-OMON57962Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of encorafenib and binimetinib in melanoma, sponsored by Leiden University Medical Center. Primary endpoint: ctDNA dynamics over time. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON57962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57962.